EcoDrugPlus

Prostaglandin E Receptor 1b (Subtype Ep1)

Ensembl ID : ENSOMYG00000004014
Gene Symbol: PTGER1B
1 Cross references
158 Possible Orthologues:

Prostaglandin E Receptor 1b (Subtype Ep1)

Ensembl ID : ENSOMYG00000024118
Gene Symbol: PTGER1B
1 Cross references
159 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSOMYG00000026486
Gene Symbol: PTGER2A
1 Cross references
196 Possible Orthologues:

Prostaglandin E Receptor 2a (Subtype Ep2)

Ensembl ID : ENSOMYG00000012201
Gene Symbol: PTGER2A
1 Cross references
198 Possible Orthologues:

Prostaglandin E Receptor 2b (Subtype Ep2)

Ensembl ID : ENSOMYG00000008615
Gene Symbol: PTGER2B
1 Cross references
163 Possible Orthologues:

Prostaglandin E Receptor 2b (Subtype Ep2)

Ensembl ID : ENSOMYG00000030446
Gene Symbol: PTGER2B
1 Cross references
164 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) A

Ensembl ID : ENSOMYG00000030324
Gene Symbol: PTGER4A
1 Cross references
196 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) B

Ensembl ID : ENSOMYG00000000842
Gene Symbol: PTGER4B
1 Cross references
195 Possible Orthologues:

Prostaglandin E Receptor 4 (Subtype Ep4) B

Ensembl ID : ENSOMYG00000041358
Gene Symbol: PTGER4B
1 Cross references
195 Possible Orthologues:

Prostaglandin F Receptor (Fp)

Ensembl ID : ENSOMYG00000003308
Gene Symbol: PTGFR
1 Cross references
195 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSOMYG00000022323
Gene Symbol: PTGIR
1 Cross references
181 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2a

Ensembl ID : ENSOMYG00000045785
Gene Symbol: PTGS2A
1 Cross references
156 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).